Viewing Study NCT05222932


Ignite Creation Date: 2025-12-24 @ 9:27 PM
Ignite Modification Date: 2025-12-27 @ 11:08 AM
Study NCT ID: NCT05222932
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-07
First Post: 2022-02-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
Sponsor: TILT Biotherapeutics Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module